Navigation Links
Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results
Date:2/5/2009

estone payments from Shire. The Company's 2009 net cash burn is expected to be approximately $20 million. Amicus anticipates ending 2009 with approximately $100 million in cash.

Shire HGT Collaboration

In November 2007, Amicus entered into a strategic collaboration with Shire Human Genetic Therapies, Inc., a wholly-owned subsidiary of Shire plc, to jointly develop Amicus' three lead pharmacological chaperone compounds for lysosomal storage disorders, Amigal, Plicera and AT2220. In this collaboration, valued at up to $440 million including an up front payment and success based clinical and sales milestones and excluding royalties and cost sharing, Shire reimburses world-wide development costs on a 50/50 basis, and in return Shire received rights to commercialize these products outside of the U.S. while Amicus retains all rights to commercialize these products in the U.S. In addition, Amicus leads development operations through the end of Phase 2 clinical trials. The companies then share responsibility for Phase 3 clinical trial development leveraging Shire's significant ex-U.S. regulatory and clinical experience as well as its commercial infrastructure.

Additional Financial Results & Notes

On a reported basis, the net loss attributable to common stockholders for the three months ended December 31, 2008, was $14.2 million as compared to $11.8 million for the same period in 2007. On a non-GAAP basis, the net loss for the three months ended December 31, 2008, was $12.5 million as compared to $10.7 million in the same period in 2007.

Amicus recorded revenue during the fourth quarter of 2008 representing two different revenue streams from the Shire agreement. Upon signing the agreement, Amicus received an upfront payment of $50 million that will be recognized as revenue on a straight-line basis over 18 years from the date of the agreement. In the fourth quarter 2008
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
2. Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
3. Amicus Therapeutics to Present at Lazard Capital Markets Healthcare Conference
4. Amicus Therapeutics Announces Third Quarter 2008 Financial Results
5. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
6. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
7. Amicus Therapeutics Opens Research Facility in San Diego
8. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
9. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
10. Amicus Therapeutics Announces First Quarter 2008 Financial Results
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... St. Louis, MO (PRWEB) August 21, 2014 ... premier, full service biopharmaceutical contract development and manufacturing ... selected by Progenics Pharmaceuticals, Inc., an oncology company ... targeting and treating cancer, to manufacture the anti-prostate ... Progenics’ PSMA ADC product candidate. Under the ...
(Date:8/20/2014)... , Aug. 20, 2014 Clintrax ... services located in Raleigh, NC ... Evans as Vice President of Administration. ... will oversee all corporate processes, including their alignment ... Clintrax Global, Brad worked as an HR executive, ...
(Date:8/20/2014)... the first time, chemists have succeeded in measuring vibrational ... resolution. The study reveals how vibration of a single ... , The study was performed at the University ... the University of Jyvskyl works as a visiting fellow ... the study. The second team was lead by Professor ...
(Date:8/20/2014)...  Decision Resources Group finds that the vascular access device market ... India and China ... to the size of the United States ... much faster growth as a result of strong economic expansion, improving ... findings from Decision Resources Group,s coverage of the BRIC vascular access ...
Breaking Biology Technology:Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3Clintrax Global, Inc. Announces Addition to Executive Team 2Seeing a molecule breathe 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 3
... , part of Vocollect, a business unit of Intermec, ... Pine Grove Nursing Center has implemented AccuNurse® voice technology. ... to patients and residents, while preparing for 2014 healthcare reform ... CNAs to observe and accurately document care needs while they ...
... Northwest Biotherapeutics (OTC.BB: NWBO) (NW Bio) today announced that ... trial sites open and recruiting by the end of Q4, ... immune therapy for Glioblastoma multiforme (GBM), the most lethal form ... projections it had set for the two preceding quarters (Q2 ...
...   Sigma-Aldrich ... and High Technology company, announced it has signed an agreement ... biopharmaceutical testing services, from Avista Capital Partners for $350 million ... including regulatory clearance, and is expected to close in the ...
Cached Biology Technology:Pine Grove Nursing Center Uses AccuNurse Interactive Care to Improve Care and Service Delivery 2Pine Grove Nursing Center Uses AccuNurse Interactive Care to Improve Care and Service Delivery 3NW Bio Reaches 25 Clinical Trial Sites Open and Recruiting By the End of Q4, 2011 2NW Bio Reaches 25 Clinical Trial Sites Open and Recruiting By the End of Q4, 2011 3NW Bio Reaches 25 Clinical Trial Sites Open and Recruiting By the End of Q4, 2011 4Sigma-Aldrich to Acquire BioReliance; Extending Its Reach into Biopharmaceutical Testing and Services 2Sigma-Aldrich to Acquire BioReliance; Extending Its Reach into Biopharmaceutical Testing and Services 3Sigma-Aldrich to Acquire BioReliance; Extending Its Reach into Biopharmaceutical Testing and Services 4
(Date:8/20/2014)... Virginia Tech,s Wu Feng has built upon a National ... in the Cloud" program, and synergistically complemented it with ... the Air Force on "big computing" for mini-drones and ... Institutes of Health on "big data" for the life ... aspects from each grant, he was able to tell ...
(Date:8/20/2014)... about 4,000 members, it triggers an important first stage ... type of comb used for rearing male reproductive, called ... Neurobiology and Behaviour at Cornell University, led by Michael ... colonies. The results are published in Springer,s journal ... Reproduction isn,t always a honeybee colony,s top priority. ...
(Date:8/20/2014)... , Aug. 20, 2014  The second annual ... in Tampa, Florida on ... with Steven Rahman, Director, Technology and Strategy at Samsung, ... Experian. The theme of this year,s event is ... "Biometrics UnPlugged: Mobility at the ...
Breaking Biology News(10 mins):The internet was delivered to the masses; parallel computing is not far behind 2The internet was delivered to the masses; parallel computing is not far behind 3The internet was delivered to the masses; parallel computing is not far behind 4Worker bees 'know' when to invest in their reproductive future 2Biometrics UnPlugged: Mobility at the Crossroads of Commerce & Privacy to Feature Interactive Sessions with Samsung and Experian 2
... developer and manufacturer of advanced molecular sensing and imaging ... that it has signed exclusive distribution deals for both ... markets covered include Australia, New Zealand, The Netherlands, ... Greece, Turkey, and Russia. The values of the ...
... 23 GenVault Corporation, the leader in ambient temperature ... announced that David Wellis, Ph.D., GenVault,s President and CEO, ... place on October 26th and 27th in La Jolla, ... an overview of the company together with recent customer, ...
... Inc., the commercial arm of the Open Microscopy Environment ... to announce its collaboration with the American Society of ... Image Library." The ASCB has been awarded a $2.5M ... Grand Opportunities program, as part of the American Reinvestment ...
Cached Biology News:Spectros Signs New International Distribution Deals 2GenVault Corporation to Present at the 2009 BIOCOM Investor Conference 2Glencoe Software to Support the ASCB 'Stimulus Grant' to Build Virtual Image Library of the Cell 2
Polaroid black & white positive, 3 x 4 inch pack film, ISO 3000/ 36 ASA DIN (20 expsures). For use in the Polaroid Direct Copy Camera (PHC34)....
Applications: (+) Immunocytochemistry and immunohistochemistry...
For the quantitative determination of canine Interferon gamma,(IFN-γ) concentrations in cell culture supernates, serum and,plasma....
Non-Protein Peroxidase Stabilizer , 1 L...
Biology Products: